Navigation Links
Bacterial Biofilm Infections: Personalizing Patient Treatment
Date:5/23/2017

Bacterial biofilms, surface adherent communities of bacteria that are encased in a secreted extracellular matrix of polymeric molecules, can cause diverse pathologies ranging from food poisoning and catheter infections to gum disease and the rejection of medical implants. Though the economic impact of biofilms is in the tens of billions of dollars per year, there is currently a paucity of means for preventing their formation or treating them once they are established. Compared to the free-floating “planktonic” lifestyle, within biofilms bacteria adopt differential gene expression profiles, have heightened resistance to antibiotics (up to 1,000-fold), and are less detectable/ accessible to the immune system. The current approach for treating biofilm infections is far from optimal: antibiotics are administered in a trial-and-error manner.

To reduce the time required for eliminating a biofilm infection, lower the cost of treatment, and improve the patient’s experience, it would be helpful to empirically identify the most efficacious antibiotic prior to initiating treatment. Towards this end, Dr. Alex Mira and colleagues at the Centre for Advanced Research in Public Health (Valencia, Spain) recently announced an initiative to personalize the treatment of biofilm infections using a novel ex vivo antibiotic screening assay. In their protocol, bacteria from biofilm growing on a patient’s catheter, medical implant, infected gums, etc. are isolated and grown in specialized electronic microtiter plates (E-Plates®) in the presence or absence of diverse antibiotics. An xCELLigence instrument, which uses the principle of cellular impedance to track the real-time growth of both the bacteria and their extracellular matrix inside E-Plates, is then used to rank order the efficacy of the different antibiotics tested. Using this approach, in just 8 hours a physician can identify the optimal therapeutic course of action on a patient by patient basis.

The primary objective of this initiative’s ongoing first phase is to determine how accurate the ex vivo xCELLigence assay is for predicting antibiotic efficacy in patients. With the backing of Minister of Health Carmen Montón, the project has been fast-tracked and Mira’s team is expecting to enroll 100 patients over the first year. If the clinical findings reflect the preliminary data, this personalized approach will revolutionize how biofilm infections are treated in the near future.

About xCELLigence® RTCA
xCELLigence® Real Time Cell Analysis (RTCA) instruments utilize gold microelectrodes embedded in the bottom of microtiter wells to non-invasively monitor the status of adherent cells using the principle of cellular impedance. In short, cells act as insulators – impeding the flow of a miniscule electric current between electrodes. This impedance signal is measured automatically, at an interval defined by the user, and provides an extremely sensitive readout of cell number, cell size, cell-substrate attachment strength, and cell invasion/migration. xCELLigence® RTCA instruments are being used in both academia and industry for basic and applied applications ranging from bacterial biofilms and cancer immunotherapy to cardiotoxicity and drug discovery. To date xCELLigence® has been used in more than 1,250 publications, which can be viewed in a searchable library.

About ACEA Biosciences
Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance, cutting edge cell analysis platforms for life science research. ACEA’s xCELLigence® impedance-based, label-free, real-time cell analysis instruments and NovoCyte® flow cytometer are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,300 instruments have been placed globally.

For more information, click here.

For further information please contact:                                                                                    
ACEA Biosciences, Inc.                                                                                                                
Dr. Jeff Xue                                                                                                                                    
Phone: 1-858-724-0928, x3075                                                                                                
email: jxue(at)aceabio(dot)com

Read the full story at http://www.prweb.com/releases/2017/05/prweb14360614.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension
2. Forge Therapeutics Announces Novel Antibiotic Presentation at the American Society of Microbiology Conference on Antibacterial Development
3. Whitehouse Laboratories Launches Bacterial Endotoxin Testing Service
4. RPS Diagnostics Announces Canadian Approval of FebriDx® Test to Help Rapidly Differentiate Viral from Bacterial Acute Respiratory Infection at the Point of Care
5. Worcester Polytechnic Institute Researchers Study Copper to Help Cells Fight Back Against Bacterial Invaders
6. Microbiology Culture Market to Exceed US$7.59 bn by 2023, Bacterial Culture Media to Lead Growth: Transparency Market Research
7. Global Bacterial Biopesticides Market is Estimated to be Worth $1,438.6 Million by 2019, at a CAGR of 13.4% from 2014 to 2019
8. Antibacterial Drugs: World Industry and Market Prospects 2015-2025
9. MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development
10. Worlds First Biocompatible and Non-toxic Antibacterial Plastic
11. The inner workings of a bacterial black box caught on time-lapse video
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... , ... AMRI, a global contract research, development and manufacturing ... and quality of life, will now be offering its impurity solutions as a ... requirements for all new drug products, including the finalization of ICH M7 earlier ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
Breaking Biology Technology:
(Date:6/30/2017)... 30, 2017 Today, American Trucking Associations ... of face and eye tracking software, became the ... program. "Artificial intelligence and advanced ... monitor a driver,s attentiveness levels while on the ... to detect fatigue and prevent potential accidents, which ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
Breaking Biology News(10 mins):